Trends in COPD severe exacerbations, and all-cause and respiratory mortality, before and after implementation of newer long-acting bronchodilators in a large population-based cohort
The arrival of newer bronchodilators was chronologically associated with reduced trends in severe exacerbation, all-cause and respiratory-related mortality rates among people with COPD > 65 years. Our findings document population benefits on key patient-relevant outcomes in the years following the introduction of newer once-daily long-acting bronchodilators and their combinations, which were likely multifactorial. Public health efforts should focus on closing the gap between lower and higher socioeconomic status groups.
Authors
- Claudia Beaudoin (ORCID: https://orcid.org/0000-0001-9745-0611)
- Caroline Sirois (ORCID: https://orcid.org/0000-0003-3294-7883)
- Laurie Perreault
- Elhadji Anassour Laouan Sidi
- Steeve Provencher (ORCID: https://orcid.org/0000-0001-7535-9972)
- Pierre‐Hugues Carmichael
- Charles-Antoine Guay (ORCID: https://orcid.org/0009-0002-9774-9095)
- François Maltais (ORCID: https://orcid.org/0000-0002-6809-4651)
Institutions
- Université de Sherbrooke (CA)
- Institut National de Santé Publique du Québec (CA)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Université Laval (CA)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1186/s12890-024-03277-2
- Citations
- 4
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Fonds de Recherche du Québec - Santé